Verapamil
Oral
Intravenous
Class
Antiarrhythmics
Subclass
Nondihydropyridine calcium channel blockers
Substance name
Verapamil hydrochloride
Common formulations
Tablet
See also
Verapamil ER (Verelan PM®)
Verapamil SR (Verelan®, Calan SR®)
Verapamil DR (Verelan®)
Verapamil COER (Covera-HS®)
Dosage and administration
Adults patients
Treatment
AF • Rate control
Angina pectoris
Atrial flutter • Rate control
Hypertension
Stable angina
Vasospastic angina
LVOTO in patients with HCM • Off-label
Prevention
Prevention of cluster headache • Off-label
Secondary prevention
Secondary prevention of paroxysmal SVT
Other off-label uses
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Contraindications
Hypersensitivity to verapamil or its components
Hypotension or cardiogenic shock
Second- or third-degree AV block
Severe LV dysfunction
Sick sinus syndrome
WPW syndrome or Lown-Ganong-Levine syndrome
Warnings and precautions
Drug-induced liver injury
Pulmonary edema
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: C
Breastfeeding
Halt breastfeeding temporarily.
Low excretion in breastmilk (5-25%).
Undetectable levels in breastfed infants.
May potentially cause adverse effects in breastfed infants.
No overt adverse effects on lactation reported.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource